Neuroprotective Effects of Erythravine in Cerebral Ischemia-Reperfusion Injury

Background: Cerebral ischemia-reperfusion (I/R) injury remains a major cause of morbidity and mortality worldwide. It results from the temporary interruption of cerebral blood flow followed by the restoration of circulation, which paradoxically exacerbates neuronal injury through a cascade involving oxidative stress, inflammation, and excitotoxicity. The pathophysiological mechanisms include energy failure, ion imbalance, elevated intracellular calcium levels, generation of reactive oxygen species (ROS), and activation of inflammatory cytokines. These processes lead to cellular damage and death, primarily through necrosis and apoptosis. Objective: To evaluate the neuroprotective potential of Erythravine, an alkaloid derived from Erythrina mulungu, in attenuating cerebral I/R injury in rats, including antioxidant and anti-inflammatory properties, which may contribute to neuroprotection. Methodology: An experimental model of cerebral ischemia-reperfusion was induced in laboratory animals. The study involved the administration of Erythravine at therapeutic doses prior to and/or after the ischemic insult. Parameters such as infarct volume, neurological deficit scoring, oxidative stress markers (e.g., MDA, SOD, GSH), inflammatory cytokine levels (e.g., TNF-α, IL-1β), and histopathological changes in brain tissue were measured to assess the extent of neuronal damage and the protective effects of Erythravine. Results: Erythravine-treated groups demonstrated a significant reduction in infarct size compared to controls. There was also marked improvement in neurological scores and a decrease in oxidative stress markers, indicating a reduction in lipid peroxidation and enhanced antioxidant defense. Furthermore, histological analysis revealed preserved neuronal architecture, and pro-inflammatory cytokine levels were notably reduced, suggesting an anti-inflammatory effect. Conclusion: Erythravine exhibits a promising neuroprotective effect in cerebral ischemia-reperfusion injury by modulating oxidative stress and inflammatory responses. These findings support its potential as a therapeutic agent in the management of ischemic stroke and related neurological disorders. Further studies are warranted to elucidate its molecular mechanisms and evaluate its clinical applicability.